Trial Profile
A pivotal phase III trial of memantine extended release (ER) /donepezil HCl in patients with moderate to severe Alzheimer's disease on a stable dose of donepezil.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2015
Price :
$35
*
At a glance
- Drugs Donepezil/memantine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ADS-DEM-DM303
- Sponsors Adamas Pharmaceuticals
- 18 May 2012 New trial record